Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across …
Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
[HTML][HTML] High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the …
A Marabelle, M Fakih, J Lopez, M Shah… - The Lancet …, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of …
response to immune checkpoint blockade. We prospectively explored the association of …
Immunotherapy in lung cancer: current landscape and future directions
Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …
greater understanding of lung cancer biology has led to the development of many effective …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of …
advanced stage disease. We aimed to assess the antitumour activity and safety of …